MX2022013939A - Celulas madre para el tratamiento de enfermedades respiratorias. - Google Patents

Celulas madre para el tratamiento de enfermedades respiratorias.

Info

Publication number
MX2022013939A
MX2022013939A MX2022013939A MX2022013939A MX2022013939A MX 2022013939 A MX2022013939 A MX 2022013939A MX 2022013939 A MX2022013939 A MX 2022013939A MX 2022013939 A MX2022013939 A MX 2022013939A MX 2022013939 A MX2022013939 A MX 2022013939A
Authority
MX
Mexico
Prior art keywords
treatment
stem cells
respiratory disorders
respiratory tract
disorders
Prior art date
Application number
MX2022013939A
Other languages
English (en)
Spanish (es)
Inventor
Åkerlund Evy Lundgren
Christina Uvebrant
Sandra Lindstedt
Moreno Tania Ramos
Original Assignee
Xintela Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xintela Ab filed Critical Xintela Ab
Publication of MX2022013939A publication Critical patent/MX2022013939A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Transplantation (AREA)
MX2022013939A 2020-05-07 2021-05-07 Celulas madre para el tratamiento de enfermedades respiratorias. MX2022013939A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20173592 2020-05-07
PCT/EP2021/062111 WO2021224449A1 (en) 2020-05-07 2021-05-07 Stem cells for treatment of respiratory disorders

Publications (1)

Publication Number Publication Date
MX2022013939A true MX2022013939A (es) 2023-02-09

Family

ID=70738255

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013939A MX2022013939A (es) 2020-05-07 2021-05-07 Celulas madre para el tratamiento de enfermedades respiratorias.

Country Status (11)

Country Link
US (1) US20230346843A1 (https=)
EP (1) EP4146234A1 (https=)
JP (1) JP7821414B2 (https=)
KR (1) KR20230008159A (https=)
CN (1) CN116018149A (https=)
AU (1) AU2021266603A1 (https=)
BR (1) BR112022022355A2 (https=)
CA (1) CA3177704A1 (https=)
IL (1) IL297902A (https=)
MX (1) MX2022013939A (https=)
WO (1) WO2021224449A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202103890D0 (en) * 2021-03-19 2021-05-05 Amniotics Ab Stem cells for use in reducing the immune response following organ transplantation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007099337A1 (en) * 2006-03-01 2007-09-07 Cartela R&D Ab Expansion and differentiation of mesenchymal stem cells
CN110177560A (zh) * 2016-12-28 2019-08-27 智再如股份有限公司 活体组织损伤的修复剂以及该修复剂的制造方法
ES2870776T3 (es) 2017-01-27 2021-10-27 Xintela Ab Prevención y tratamiento de daños o enfermedades de los huesos y cartílagos
CN116590227A (zh) * 2017-03-03 2023-08-15 日本乐敦制药株式会社 间充质干细胞和肝疾病治疗剂
WO2018159432A1 (ja) * 2017-03-03 2018-09-07 ロート製薬株式会社 間葉系幹細胞及び医薬組成物

Also Published As

Publication number Publication date
CN116018149A (zh) 2023-04-25
BR112022022355A2 (pt) 2022-12-13
JP2023524150A (ja) 2023-06-08
CA3177704A1 (en) 2021-11-11
US20230346843A1 (en) 2023-11-02
JP7821414B2 (ja) 2026-02-27
EP4146234A1 (en) 2023-03-15
KR20230008159A (ko) 2023-01-13
WO2021224449A1 (en) 2021-11-11
AU2021266603A1 (en) 2022-12-08
IL297902A (en) 2023-01-01

Similar Documents

Publication Publication Date Title
MX2021013197A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
CL2022003510A1 (es) Inhibidores de cisteína proteasas y sus métodos de uso
MX2021013193A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
CO2023015484A2 (es) Compuesto, composiciones y métodos para el tratamiento de trastornos
CO2021014694A2 (es) Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio
MX2022003466A (es) Interrupción de los tejidos tumorales al dirigir la proteína de activación de fibroblastos (fap).
CL2018001089A1 (es) Sales de valbenazina y polimorfos de las mismas.
GT201200258A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
UY38800A (es) Receptor de antígeno quimérico (car) anti-hk2
AR115566A1 (es) Composiciones y procedimientos para el tratamiento del cáncer
CL2024001566A1 (es) Moduladores de la vía integrada del estrés
CL2023001580A1 (es) Uso de roluperidona para tratar síntomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroprotección
ZA202000680B (en) Obinutuzumab treatment of a dlbcl patient subgroup
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
AR131235A1 (es) Formas cristalinas de n,n-dimetiltriptamina y métodos para usarlas
CO2024007013A2 (es) Isoxazolidinas como inhibidores de ripk1 y uso de estas
CL2022002259A1 (es) Anticuerpos anti-axl y composiciones
MX2022013939A (es) Celulas madre para el tratamiento de enfermedades respiratorias.
CO2020004984A2 (es) Proceso para preparar el benzotiofen-2-il boronato
MX2021009443A (es) Composiciones que contienen bacterias productoras de bacillaeno o preparaciones de las mismas.
CL2023003209A1 (es) Composición farmacéutica de pembrolizumab y su uso
UY37907A (es) 3-fenilquinazolin-4 (3h)-onas sustituidas y sus usos
BR112022019423A2 (pt) Moduladores de hemoglobina
MX2023007479A (es) Composiciones de cannabidiol y usos de las mismas.
CL2019002315A1 (es) Nuevo uso médico del compuesto iii.